Evidence map›Paper›PMID 29462444›Full record

ArticleJournal of travel medicine2018

Business travel-associated illness: a GeoSentinel analysis.

Lin H Chen, Karin Leder, Kira A Barbre, Patricia Schlagenhauf, Michael Libman, Jay Keystone, Marc Mendelson, Philippe Gautret, Eli Schwartz, Marc Shaw and 7 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of travel medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. What Is the Impact of Lockdowns on Dengue?Current infectious disease reports · 2021
    Review
  10. GeoSentinel: past, present and future†.Journal of travel medicine · 2020
    Review
  11. Malaria in travellers in the time of corona.Journal of travel medicine · 2020
    Article
  12. Article
  13. Review
  14. Malaria Disease and Chemoprophylaxis Usage among Israeli Travelers to Endemic Countries.The American journal of tropical medicine and hygiene · 2020
    Article
  15. Dengue vaccine development: status and future.Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020
    Review
  16. Yellow Fever in Travelers.Current infectious disease reports · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 15 institutions in 8 countries.

Lin H ChenMount Auburn Hospital, Cambridge, Massachusetts, and Harvard Medical School, Boston, MA, USA.
Karin LederRoyal Melbourne Hospital and School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Kira A BarbreDivision of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Patricia SchlagenhaufUniversity of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland.
Michael LibmanMontreal General Hospital and McGill University, Montreal, Quebec, Canada.
Jay KeystoneToronto General Hospital and University of Toronto, Toronto, Ontario, Canada.
Marc MendelsonDivision of Infectious Diseases & HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Philippe GautretAix Marseille Université, IHU-Méditerranée Infection, Marseille, France.
Eli SchwartzThe Chaim Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine Tel-Aviv University, Israel.
Marc ShawWorldwise Travellers Health Centres New Zealand and James Cook University, Australia.
Sue MacDonaldMedicine and Quality, Interior Health, and University of British Columbia, Kelowna, British Columbia, Canada.
Anne McCarthyOttawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.
Bradley A ConnorThe New York Center for Travel and Tropical Medicine and Weill Medical College of Cornell University, New York, NY, USA.
Douglas H EspositoDivision of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Davidson HamerCenter for Global Health and Development, Boston University School of Public Health, and Boston University School of Medicine, Boston, MA, USA.
Mary E WilsonDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
GeoSentinel Surveillance Network
Boston University · USCenters for Disease Control and Prevention · USUniversity of Zurich · CHAix-Marseille Université · FRCornell University · USInterior Health · CAMontreal General Hospital · CAMount Auburn Hospital · USTel Aviv University · ILThe Royal Melbourne Hospital · AUUniversity of California, San Francisco · USUniversity of Cape Town · ZAUniversity of Ottawa · CAUniversity of Toronto · CAWorldwise Travellers Health & Vaccination Centres · NZ

Funding

Intramural CDC HHS CC999999Medical Research Council G0701652NCEZID CDC HHS U50 CK000189
6 · The paper itself

Abstract

Background: Analysis of a large cohort of business travelers will help clinicians focus on frequent and serious illnesses. We aimed to describe travel-related health problems in business travelers. Methods: GeoSentinel Surveillance Network consists of 64 travel and tropical medicine clinics in 29 countries; descriptive analysis was performed on ill business travelers, defined as persons traveling for work, evaluated after international travel 1 January 1997 through 31 December 2014. Results: Among 12 203 business travelers seen 1997-2014 (14 045 eligible diagnoses), the majority (97%) were adults aged 20-64 years; most (74%) reported from Western Europe or North America; two-thirds were male. Most (86%) were outpatients. Fewer than half (45%) reported a pre-travel healthcare encounter. Frequent regions of exposure were sub-Saharan Africa (37%), Southeast Asia (15%) and South Central Asia (14%). The most frequent diagnoses were malaria (9%), acute unspecified diarrhea (8%), viral syndrome (6%), acute bacterial diarrhea (5%) and chronic diarrhea (4%). Species was reported for 973 (90%) of 1079 patients with malaria, predominantly Plasmodium falciparum acquired in sub-Saharan Africa. Of 584 (54%) with malaria chemoprophylaxis information, 92% took none or incomplete courses. Thirteen deaths were reported, over half of which were due to malaria; others succumbed to pneumonia, typhoid fever, rabies, melioidosis and pyogenic abscess. Conclusions: Diarrheal illness was a major cause of morbidity. Malaria contributed substantial morbidity and mortality, particularly among business travelers to sub-Saharan Africa. Underuse or non-use of chemoprophylaxis contributed to malaria cases. Deaths in business travelers could be reduced by improving adherence to malaria chemoprophylaxis and targeted vaccination for vaccine-preventable diseases. Pre-travel advice is indicated for business travelers and is currently under-utilized and needs improvement.

Indexed as

Sentinel SurveillanceTravelAdultAfrica South of the SaharaAgedAsiaCommerceDiarrheaEuropeFemaleHumansMalariaMaleMiddle AgedNorth AmericaOccupational Medicine

Identifiers

PMID29462444
PMCPMC5824651
OpenAlexW2790982539

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.